Setting new standards in information exchange for the pharmaceutical and biotech industry
A Program for Chief Medical Officers in Emerging Life Sciences, November 3-4, 2014
October 21, 2014
The role of a Chief Medical Officer is one that takes courage given the numerous hats worn simultaneously. For a CMO in early, emerging and even midsize life science companies, it can be a solitary one. In addition to the responsibilities of driving clinical development, drug safety, medical affairs, regulatory strategy and CRO management, CMOs may also need to meet the needs of investors and help position for an appropriate exit.
On November 3-4 in San Francisco, our team is hosting a program designed for CMOs of Emerging Biotechs thanks to an idea suggested by Dr Elizabeth Stoner, Managing Director, MPM Capital. The program is dedicated to accomplishing two goals:
1. To bring together CMO executives to address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits.
2. To create a network of CMOs from small to midsize life science companies to share ideas, solutions and support.
Chaired by Dr Lee Allen, CMO, Spectrum Pharmaceuticals and Dr Pamela Palmer, CMO & Co-Founder, AcelRX Pharmaceuticals, Inc., the keynotes include:
The Jazz Pharmaceutical Turn Around Case Study
Dr Jeffrey Tobias, EVP, R&D & CMO, Jazz Pharmaceuticals
Life of a CMO Pre and Post IPO
Dr Jakob Dupont, CMO & SVP, OncoMed
Regulatory Approval and Market Access in Europe
Dr Thomas Lonngren, Former Head, EMA
The program also includes an entire afternoon on alternative clinical designs led by Onyx Pharmaceuticals. For more information on the CMOW event, please visit www.theconferenceforum.org.